Date published: 2025-9-12

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR4C45 Inhibitors

OR4C45 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of OR4C45, an olfactory receptor (OR) belonging to the extensive family of G-protein-coupled receptors (GPCRs). Olfactory receptors such as OR4C45 are responsible for detecting odorant molecules in the nasal epithelium and initiating the signaling pathways that lead to the perception of smell. When an odorant binds to OR4C45, it activates a G-protein-mediated cascade that results in changes in cellular signaling and the transmission of signals to the brain. In addition to their primary role in olfaction, olfactory receptors like OR4C45 are increasingly recognized for their presence in non-olfactory tissues, where they may participate in various cellular signaling processes. Inhibitors of OR4C45 interfere with the receptor's ability to bind its ligand or initiate downstream signaling.

By utilizing OR4C45 inhibitors, researchers can explore the specific functions of this receptor in both sensory and non-sensory contexts. Blocking OR4C45 provides insight into how its inhibition impacts olfactory signal transduction, allowing for a detailed understanding of the molecular mechanisms governing smell perception. Additionally, since olfactory receptors have been detected in tissues outside the olfactory system, inhibiting OR4C45 can shed light on its potential role in other physiological processes such as cellular communication, metabolic regulation, or tissue homeostasis. Studying OR4C45 inhibitors helps clarify the broader functions of olfactory receptors, contributing to the understanding of how these GPCRs influence a wide range of cellular activities and interact with other signaling pathways in the body.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Actinomycin D may inhibit OR4C45 expression by interfering with RNA polymerase activity, leading to reduced transcription of OR4C45 mRNA.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

Cycloheximide inhibits protein synthesis, potentially reducing OR4C45 levels and its subsequent function in olfactory detection.

Puromycin

53-79-2sc-205821
sc-205821A
10 mg
25 mg
$163.00
$316.00
436
(1)

Puromycin integrates into protein chains during synthesis, potentially decreasing OR4C45 levels and its involvement in olfactory perception.

Anisomycin

22862-76-6sc-3524
sc-3524A
5 mg
50 mg
$97.00
$254.00
36
(2)

Anisomycin may inhibit OR4C45 expression by interfering with protein synthesis, leading to reduced levels of functional OR4C45 protein.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

Cisplatin may modulate transcription factors involved in OR4C45 expression, potentially reducing the production of OR4C45 protein.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$32.00
$170.00
$385.00
63
(1)

Etoposide can impact OR4C45 expression through its effects on DNA topoisomerase II, potentially altering the transcription of OR4C45.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

Camptothecin may impact OR4C45 expression by affecting DNA topoisomerase I, potentially altering the transcription of OR4C45.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

Doxorubicin may affect OR4C45 expression through its impact on DNA and associated cellular stress responses, potentially altering OR4C45 expression.

Ellipticine

519-23-3sc-200878
sc-200878A
10 mg
50 mg
$142.00
$558.00
4
(1)

Ellipticine might impact OR4C45 expression through its effects on DNA and potential alterations in the expression of OR4C45.

Mitomycin C

50-07-7sc-3514A
sc-3514
sc-3514B
2 mg
5 mg
10 mg
$65.00
$99.00
$140.00
85
(5)

Mitomycin C could affect OR4C45 expression by causing DNA crosslinking, potentially leading to altered OR4C45 expression levels.